Result
€94,982 ▲ 135%
The result rose in 2025 from €40,432 to €94,982.
DILMED
Overview
Lifetime
2 annual accounts with figures on one time axispeak €121,897 (2025)
€121,897▲ 114%
peak €94,982 (2025)
€94,982▲ 135%
peak €140,414 (2025)
€140,414▲ 209%
€86,954▲ 238%
Board1 name since 2024
1 director
Documentsfilings and deeds
27-08-202627 days late
2025micro format
Gross margin from €56,935 to €121,897Result from €40,432 to €94,982Equity from €45,432 to €140,414Debts from €25,691 to €86,954Cash from €31,279 to €127,077
Key points
from the 2025 annual accountsDebts
€86,954 ▲ 238%
Debts rose by €61,263 in 2025.
Investments
€2,528 5.9 × depreciation
Green is investment, beige is depreciation.
2025 accounts filed 27 days after the deadline
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,326 companies had the same profile as DILMED has now. Each dot stands for 99 companies, two years later.
95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,326 companies, not a prediction for DILMED. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1006892167
Incorporation
Founding capital of €5,000, 100 shares · Founder: (comparant requérant les statuts) · Appointment: (director) · published on 11-03-2024 · Gazette deed
First establishment
Nerviërslaan 111, Etterbeek
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DILMED Etterbeek | €227,368 | €121,897 | 61.8% | - |
| HEMATHEM Auderghem | €216,398 | €114,754 | 97.3% | - |
| DiaBELM Sint-Gillis (bij-Brussel) | €207,758 | €133,533 | 81.9% | - |
| ALIVRIA Forest | €248,473 | €137,513 | 63.0% | - |
| KH Med Liège | €220,360 | €126,958 | 63.8% | - |
| Dr. Lien Devuyst, NKO Ghent | €214,276 | €113,611 | 89.3% | - |
| Reunite Bruges | €202,070 | €119,464 | 86.3% | - |
These companies have the same main activity as DILMED: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €202,000 and €248,000, founded between 2023 and 2024.
Official details
Source: KBO- Status
- Active since 07-03-2024Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.357.152.1611040 Etterbeek, since 07-03-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 28-12-2025
Annual accounts 2025
- €121,897▲ 114%
- ≈ €230,000estimated
- €94,982▲ 135%
- €140,414▲ 209%
- €227,368▲ 220%
- Filing
- Filed on 27-08-2026
Insights on DILMED
DILMED has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €140,414 and a net result of €94,982.
Its solvency ranks better than 49% of 21,322 sector peers (NACE 86, financial year 2025).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
micro format, filed on 27-08-2026, 27 days late€121,897
▲ 114%
€121,466
▲ 113%
€94,982
▲ 135%
€138,317
▲ 222%
61.8%
▼ 2.1 percentage points
2.59
▼ 0.08
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €230,000. Estimated: probably between €190,000 and €300,000.
Balance sheet
balance sheet total €227,368 on 31-12-2025What the company ownsHow it is paid for
in euro
in euro
Position in the sector
61.8%
Higher than 49% of 21,322 companies in 2025.
2.59
Higher than 48% of 20,872 companies in 2025.
41.8%
Higher than 77% of 21,172 companies in 2025.
DILMED
Middle half of the sector
80% of the sector
Micro accounts in human health (NACE 86)
Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: middle half
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 |
|---|---|---|---|
| Balance sheet: assets | |||
20/58 |
227,368 | 71,123 | |
21/28 |
2,097 | 2,500 | |
22/27 |
2,097 | - | |
24 |
2,097 | - | |
28 |
0 | 2,500 | |
29/58 |
225,271 | 68,623 | |
40/41 |
47,763 | 1,512 | |
40 |
47,763 | 1,512 | |
54/58 |
127,077 | 31,279 | |
490/1 |
50,432 | 35,832 | |
| Balance sheet: equity and liabilities | |||
10/49 |
227,368 | 71,123 | |
10/15 |
140,414 | 45,432 | |
10/11 |
5,000 | 5,000 | |
14 |
135,414 | 40,432 | |
17/49 |
86,954 | 25,691 | |
42/48 |
86,954 | 25,691 | |
44 |
19,571 | 64 | |
440/4 |
19,571 | 64 | |
45 |
56,778 | 16,479 | |
450/3 |
56,778 | 16,479 | |
47/48 |
10,605 | 9,148 | |
| Income statement | |||
9900 |
121,897 | 56,935 | |
630 |
431 | - | |
9901 |
121,466 | 56,935 | |
75/76B |
1 | 9 | |
75 |
1 | 9 | |
65/66B |
2 | 33 | |
65 |
2 | 33 | |
9903 |
121,465 | 56,911 | |
67/77 |
26,483 | 16,479 | |
9904 |
94,982 | 40,432 | |
9905 |
94,982 | 40,432 | |
| Appropriation of the result | |||
9906 |
135,414 | 40,432 | |
14P |
40,432 | - | |
| Social balance sheet | |||
Hours worked1013 |
- | 0 | |
| Document | |||
The notes to these accounts have 6 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 27-08-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank2025 annual accounts filed 27 days after the deadline. Filed on 27 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00432716.
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 |
|---|---|---|---|
| 121,897 | - | ||
| 95,413 | - | ||
| 2,528 | 2,500 | ||
| 95,798 | - | ||
| 138,317 | 42,932 | ||
| 61.8% | 63.9% | ||
| 2.59 | 2.67 | ||
| 0.62 | 0.57 | ||
| 67.6% | 89.0% | ||
| 41.8% | 56.8% | ||
| over 100 | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Social balance sheet
| Item | 31-12-2024 |
|---|---|
| Employees at the balance-sheet date | 0 |
| full-time | 0 |
| part-time | 0 |
Source: social balance sheet in the 2024 annual accounts
Investments
fixed assets acquired| Item | 2025 | 2024 |
|---|---|---|
| Tangible fixed assets | €2,528 | - |
| Financial fixed assets | - | €2,500 |
| €431 | - |
Source: notes to the 2024 to 2025 annual accounts (statement of fixed assets)
Insights on DILMED
The operating result for 2025 is 113% higher than in 2024.
Debt's share of the balance-sheet total rises from 36.1% to 38.2%. Equity and debt are higher.
Board & ownership
Board
1 director, since incorporationDirector (not named in the articles)
since 07-03-2024
term without a fixed end
listed in the 2025 annual accounts, filed on 27-08-2026
Mandates through the years
1 name, the dashed line is todayDirector (not named in the articles)
Board
Mandates as a list
-
- Director (not named in the articles), from 07-03-2024 to date
Control
Founder
This company
DILMED
Equity €140,414
Profit €94,982 in 2025
Capital
- Contribution
- €5,000
- Shares
- 100
- Contribution per share
- €50
- Equity per share
- €1,404 in 2025
- Source
- deed of 11-03-2024
Articles of association
deed of 11-03-2024 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- 100 shares
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last day of June at 18:00
- Statutory auditorA statutory auditor is a registered auditor who checks the annual accounts. Small companies need not have one.
- No statutory auditor
Shareholders
At incorporation
deed of 11-03-2024 ↗
- 100 shares (100%) · €5,000 in cash
Network & group
No group
DILMED has no parent and no holdings in its annual accounts. is the only director. DILMED shares no director with another company.
At the same address
Nerviërslaan 111, 1040 Etterbeek · 3 other companies| OSTEOFORMED
establishment since 16-01-2015 · founded in 2010 |
total assets €90,046 (2025) 0822.895.144 |
| Diluiso, Giuseppe (sole trader)
establishment since 01-01-2023 |
founded in 2023 0797.703.254 |
| Decupère, Yannick (sole trader)
establishment since 01-09-2014 |
founded in 2003 0815.755.251 |
Timeline
Timeline
6 events since 2024Filings
Financial
Establishments
202420252026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBmicro format · 27 days late
2025
Equity above €100,000 equity €140,414 ▲209% With a profit in every financial year since 2024, equity grows to €140,414.
Registered in the Peppol Directory Reachable for e-invoices through 0208:1006892167
Annual accounts 2024 filed PDFmicro format · 19 days late
2024
IncorporationFounding capital of €5,000, 100 shares · Founder: (comparant requérant les statuts) · Appointment: (director) · published on 11-03-20245 points ▸
- Founder, (comparant requérant les statuts)
- Founding capital, €5,000, 100 shares
- holds 100 shares
- Registered office clause, Avenue des Nerviens 111 boîte 7, 1040 Bruxelles
- Director appointment, (director (not named in the articles))
- The deed holds 3 more points.
First establishment Nerviërslaan 111, Etterbeek
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 1006.892.167
- VAT number
- BE 1006.892.167
- Peppol ID
- 0208:1006892167
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 07-03-2024
- Financial year
- ends on 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last day of June at 18:00deed of 11-03-2024 (in French)
- Peppol
- Reachable since 28-12-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- DILMED in French
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 11-03-2024 (in French)
Activities
NACEBEL 202586220
Specialist medical practice main activity
Codes under NACEBEL 2008
86220
Human health activities main activity
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Nerviërslaan 111 registered office 1040 Etterbeek | 07-03-2024 | 2.357.152.161 |
Buildings and parcels at the address
- Ground area
- 277 m²
- Buildings
- 150 m²
- Volume, LiDAR
- 3,335 m³
- Tallest building
- 25.4 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 21005A0406/00T004 | 277 m² | 1 · 150 m² | 25.4 m · 8 |